Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Boston Scientific Buys Substantial Stake In Korean MedTech Player

  • Boston Scientific Corporation (NYSE:BSX) has agreed to purchase Synergy Innovation Co Ltd's majority stake (~64%) of M.I.Tech Co Ltd, a publicly-traded Korean manufacturer, and distributor of medical devices for endoscopic and urologic procedures. 
  • The deal is valued at KRW 14,500 per share, representing KRW 291.2 billion or approximately $230 million.
  • M.I.Tech offers HANAROSTENT technology, a family of conformable, non-vascular, self-expanding metal stents, which Boston Scientific in Japan has distributed since 2015. 
  • Non-vascular gastrointestinal and airway stents help clear occlusions or strictures in various areas of a patient's anatomy, including the biliary tree, pancreatic duct, esophagus, colon, and duodenum. 
  • In many cases, stent placement is minimally invasive and may aid patient recovery faster than surgery.
  • The HANAROSTENT technology features a unique hook-cross nitinol design intended to provide a natural and flexible fit within a patient's anatomy and flared ends to help prevent stent migration.
  • The company expects to complete the transaction in 2H of 2022. The impact on GAAP and adjusted EPS is expected to be immaterial in 2022.
  • Price Action: BSX shares are up 3.19% at $36.36 during the market session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.